Indegene Crescita futura
Criteri Future verificati 4/6
Indegene prevede che gli utili e i ricavi cresceranno rispettivamente di 22.2% e 13.9% all'anno. Si prevede che l'EPS crescerà di 22.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 16.8% in 3 anni.
Informazioni chiave
22.2%
Tasso di crescita degli utili
22.07%
Tasso di crescita dell'EPS
| Life Sciences crescita degli utili | 22.3% |
| Tasso di crescita dei ricavi | 13.9% |
| Rendimento futuro del capitale proprio | 16.77% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 03 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • Aug 03
Indegene Limited (NSE:INDGN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a good week for Indegene Limited ( NSE:INDGN ) shareholders, because the company has just released its latest...Articolo di analisi • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Articolo di analisi • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Articolo di analisi • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Recent updates
Articolo di analisi • Aug 03
Indegene Limited (NSE:INDGN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a good week for Indegene Limited ( NSE:INDGN ) shareholders, because the company has just released its latest...
Aggiornamento narrativa • Jun 17
INDGN: Tax Resolution Progress And Final Dividend Plans Will Support Upside
Indegene's analyst price target has been reaffirmed around ₹592, with analysts pointing to relatively unchanged assumptions on fair value, revenue growth, profit margin and future P/E, along with a slightly higher discount rate as the key drivers behind the updated view. What’s in the News for Indegene Indegene received a final assessment order from the Income Tax Department for Assessment Year 2023-24, including an income tax demand of ₹436.88441 million with transfer pricing adjustments of ₹1,234.110559 million cited in the order.Aggiornamento narrativa • Jun 02
INDGN: Tax Resolution Path And Dividend Prospects Will Drive Future Upside
Analysts have left their fair value estimate for Indegene broadly unchanged at around ₹592. A slightly higher discount rate and a marginally higher future P/E assumption are the main reasons cited for maintaining the same price target.Aggiornamento narrativa • May 14
INDGN: Upcoming Tax Assessment Outcome Will Support Future Upside
Analysts have raised Indegene's price target from ₹568.57 to ₹592.43, reflecting updated assumptions that include slightly lower discount and revenue growth rates, a marginally higher profit margin, and a modestly lower future P/E multiple. What's in the News The Income Tax Department has issued a final assessment order for Assessment Year 2023-24 with an income tax demand of ₹436.88441 million, following transfer pricing adjustments of ₹1,234.110559 million.Articolo di analisi • May 10
Investors Can Find Comfort In Indegene's (NSE:INDGN) Earnings Quality
The market was pleased with the recent earnings report from Indegene Limited ( NSE:INDGN ), despite the profit numbers...Aggiornamento narrativa • Apr 25
INDGN: Upcoming Results Review And Dividend Decision Will Support Future Upside
Indegene's analyst price target has edged down by about ₹3 per share as analysts fine-tune assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples in their updated models. What's in the News A board meeting is scheduled for April 29, 2026, to review and approve the audited consolidated financial results for Indegene and its subsidiaries for the quarter and year ended March 31, 2026, prepared under INDAS, along with the auditor's report (company filing).Aggiornamento narrativa • Apr 08
INDGN: Upcoming Board Review And RSU Allotment Will Support Future Upside
Analysts now set their price target for Indegene at ₹571.57 versus ₹603.00 earlier. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
Nuova narrativa • Apr 04
Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes
Catalysts About Indegene Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Mar 24
INDGN: Steady Fair Value And Upcoming Board Review Will Support Upside Potential
Analysts have kept Indegene's fair value estimate steady at ₹603.0, with only marginal tweaks to assumptions such as the discount rate and future P/E. This reflects fine tuning of their valuation framework rather than a major shift in view.
Nuova narrativa • Mar 14
Indegene deep undervalued stock
At ₹429–430 levels (near 52-week low), Indegene offers excellent risk-reward for 12–24 month horizon. Explosive long-term growth (35% sales CAGR, 68% profit CAGR), first $100M quarter, near-zero debt, and powerful AI/GenAI positioning in the high-growth life-sciences sector make this a high-quality compounder.Aggiornamento narrativa • Mar 05
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have trimmed their price target for Indegene slightly from about ₹606 to ₹603, reflecting modest tweaks to fair value, discount rate and future P/E assumptions while keeping revenue growth and profit margin expectations effectively unchanged. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for the quarter ended December 31, 2025 under IND AS, along with the auditors' limited review report (Key Developments).Aggiornamento narrativa • Feb 19
INDGN: Upcoming Board Decisions On RSU Allotment Will Support Continued Positive Momentum
Analysts have kept their fair value estimate for Indegene steady at ₹605.86 per share, with only minor tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding this price target reaffirmation. What's in the News A board meeting is scheduled for January 29, 2026 to review unaudited consolidated financial results for Indegene and its subsidiaries for the quarter ended December 31, 2025, prepared under IND AS, along with the auditors' limited review report (company filing).Aggiornamento narrativa • Feb 04
INDGN: Upcoming Board And Shareholder Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene from ₹609.63 to ₹605.86, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News A board meeting is scheduled for January 29, 2026, to review unaudited consolidated financial results for the quarter ended December 31, 2025, under INDAS, along with the auditors' limited review report (company filing).Articolo di analisi • Feb 02
Earnings Miss: Indegene Limited Missed EPS By 8.1% And Analysts Are Revising Their Forecasts
Last week saw the newest third-quarter earnings release from Indegene Limited ( NSE:INDGN ), an important milestone in...Aggiornamento narrativa • Jan 08
INDGN: Expanded Consulting Practice And Upcoming Meetings Will Support Continued Positive Momentum
Analysts have trimmed their fair value estimate for Indegene slightly from ₹610.25 to ₹609.63. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E that keep the overall valuation view broadly intact.Aggiornamento narrativa • Dec 23
INDGN: Upcoming Board And Shareholder Actions Will Support Continued Positive Momentum
Narrative Update on Indegene Analysts have slightly reduced their price target on Indegene by approximately ₹2 to about ₹610, reflecting marginal adjustments to discount rate and profit margin assumptions, along with a modest increase in long term revenue growth expectations. What's in the News Indegene has expanded its Consulting Practice to provide integrated strategy and transformation support for life sciences clients, aiming to deliver both strategic insight and hands on implementation across the value chain (Key Developments).Aggiornamento narrativa • Dec 09
INDGN: Upcoming Board Meeting Will Drive Continued Positive Momentum
Analysts have modestly raised their price target on Indegene by about 1 percent to approximately $612, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite largely stable profit margin and discount rate assumptions. What's in the News Board meeting scheduled on October 30, 2025 to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025 and consider equity allotments under ESOP 2020 and RSU 2020 schemes (company filing) Expansion of Indegene's Consulting Practice to provide integrated strategy and transformation support for life sciences clients facing large scale, technology driven change across the value chain (company announcement) Strategic partnership with Datavant to integrate its health data network into Indegene's NEXT Patient Recruitment platform, aiming to speed up clinical trial enrollment and improve patient recruitment, particularly in rare diseases (Datavant and company announcement) Valuation Changes The fair value estimate has risen slightly to about ₹612 per share from roughly ₹608 per share, reflecting a modest upward revision.Aggiornamento narrativa • Nov 25
INDGN: Upcoming Board Meeting and Expansions Will Drive Continued Momentum
Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions. What's in the News A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).Aggiornamento narrativa • Nov 10
INDGN: Rising Revenue and Business Expansion Will Drive Continued Outperformance
Narrative Update on Indegene Price Target Analysts have lowered their price target for Indegene from ₹644.67 to ₹609.57, citing revised expectations on future profitability and growth dynamics. What's in the News Board meeting scheduled for October 30, 2025, to review unaudited consolidated and standalone financial results for the quarter ended September 30, 2025.Articolo di analisi • Nov 02
Indegene Limited Beat Revenue Forecasts By 5.6%: Here's What Analysts Are Forecasting Next
The quarterly results for Indegene Limited ( NSE:INDGN ) were released last week, making it a good time to revisit its...Articolo di analisi • Jul 23
Getting In Cheap On Indegene Limited (NSE:INDGN) Is Unlikely
There wouldn't be many who think Indegene Limited's ( NSE:INDGN ) price-to-earnings (or "P/E") ratio of 32.5x is worth...Nuova narrativa • May 11
M&A And Cortex Integration Will Expand Enterprise Opportunities
M&A activities and AI integration signal innovation and efficiency, likely boosting topline growth and improving net margins through cost reductions.Articolo di analisi • May 03
Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year
Indegene Limited ( NSE:INDGN ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Articolo di analisi • Feb 25
Indegene Limited's (NSE:INDGN) Price Is Out Of Tune With Earnings
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 26x, you may consider...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2029 | 56,573 | 7,411 | 7,349 | N/A | 4 |
| 3/31/2028 | 49,863 | 6,557 | 7,110 | N/A | 8 |
| 3/31/2027 | 44,362 | 5,314 | 4,282 | N/A | 8 |
| 6/30/2026 | 38,128 | 4,009 | N/A | N/A | N/A |
| 3/31/2026 | 35,105 | 4,011 | 6,065 | 6,508 | N/A |
| 12/31/2025 | 32,627 | 4,390 | N/A | N/A | N/A |
| 9/30/2025 | 30,410 | 4,458 | 4,683 | 5,094 | N/A |
| 6/30/2025 | 29,236 | 4,354 | N/A | N/A | N/A |
| 3/31/2025 | 28,393 | 4,067 | 4,119 | 4,419 | N/A |
| 12/31/2024 | 27,567 | 3,839 | N/A | N/A | N/A |
| 9/30/2024 | 27,097 | 3,730 | 4,302 | 4,377 | N/A |
| 6/30/2024 | 26,586 | 3,560 | N/A | N/A | N/A |
| 3/31/2024 | 25,896 | 3,367 | 4,970 | 5,077 | N/A |
| 12/31/2023 | 25,489 | 2,907 | 3,871 | 4,100 | N/A |
| 6/30/2023 | 23,927 | 2,487 | N/A | N/A | N/A |
| 3/31/2023 | 23,061 | 2,661 | 1,114 | 1,302 | N/A |
| 3/31/2022 | 16,646 | 1,648 | 2,723 | 2,970 | N/A |
| 3/31/2021 | 9,806 | 1,857 | 1,514 | 1,720 | N/A |
| 3/31/2020 | 6,436 | 558 | N/A | 223 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di INDGN ( 22.2% all'anno) è superiore al tasso di risparmio ( 6.9% ).
Guadagni vs Mercato: Si prevede che gli utili di INDGN ( 22.2% all'anno) cresceranno più rapidamente del mercato Indian ( 16.8% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di INDGN cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di INDGN ( 13.9% all'anno) crescerà più rapidamente del mercato Indian ( 11.2% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di INDGN ( 13.9% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di INDGN sarà basso tra 3 anni ( 16.8 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 16:18 |
| Prezzo dell'azione a fine giornata | 2026/08/24 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Indegene Limited è coperta da 15 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Deep Shah | 360 ONE Capital Market Private Limited |
| Rajiv Berlia | Citigroup Inc |